Cargando…

The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity

BACKGROUND: Antihypertensive treatments have been shown to reduce the risk of Alzheimer’s disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer dif...

Descripción completa

Detalles Bibliográficos
Autores principales: Barthold, Douglas, Joyce, Geoffrey, Wharton, Whitney, Kehoe, Patrick, Zissimopoulos, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211717/
https://www.ncbi.nlm.nih.gov/pubmed/30383807
http://dx.doi.org/10.1371/journal.pone.0206705
_version_ 1783367394037596160
author Barthold, Douglas
Joyce, Geoffrey
Wharton, Whitney
Kehoe, Patrick
Zissimopoulos, Julie
author_facet Barthold, Douglas
Joyce, Geoffrey
Wharton, Whitney
Kehoe, Patrick
Zissimopoulos, Julie
author_sort Barthold, Douglas
collection PubMed
description BACKGROUND: Antihypertensive treatments have been shown to reduce the risk of Alzheimer’s disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer differential and additional protective benefits against AD compared with other AHTs, in addition to hypertension management. METHODS: In a retrospective cohort design, we examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis for 1,343,334 users of six different AHT drug treatments, 65 years of age or older (4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted for age, socioeconomic status, underlying health, and comorbidities. FINDINGS: RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting AHTs for males, (male OR = 0.931 (CI: 0.895–0.969)), but not so for females (female OR = 0.985 (CI: 0.963–1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both men (male ARB OR = 0.834 (CI: 0.788–0.884); male ACEI OR = 0.978 (CI: 0.939–1.019)) and women (female ARB OR = 0.941 (CI: 0.913–0.969); female ACEI OR = 1.022 (CI: 0.997–1.048)), but only in white men and white and black women. No association was shown for Hispanic men and women. CONCLUSION: Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.
format Online
Article
Text
id pubmed-6211717
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62117172018-11-19 The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity Barthold, Douglas Joyce, Geoffrey Wharton, Whitney Kehoe, Patrick Zissimopoulos, Julie PLoS One Research Article BACKGROUND: Antihypertensive treatments have been shown to reduce the risk of Alzheimer’s disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer differential and additional protective benefits against AD compared with other AHTs, in addition to hypertension management. METHODS: In a retrospective cohort design, we examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis for 1,343,334 users of six different AHT drug treatments, 65 years of age or older (4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted for age, socioeconomic status, underlying health, and comorbidities. FINDINGS: RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting AHTs for males, (male OR = 0.931 (CI: 0.895–0.969)), but not so for females (female OR = 0.985 (CI: 0.963–1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both men (male ARB OR = 0.834 (CI: 0.788–0.884); male ACEI OR = 0.978 (CI: 0.939–1.019)) and women (female ARB OR = 0.941 (CI: 0.913–0.969); female ACEI OR = 1.022 (CI: 0.997–1.048)), but only in white men and white and black women. No association was shown for Hispanic men and women. CONCLUSION: Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance. Public Library of Science 2018-11-01 /pmc/articles/PMC6211717/ /pubmed/30383807 http://dx.doi.org/10.1371/journal.pone.0206705 Text en © 2018 Barthold et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Barthold, Douglas
Joyce, Geoffrey
Wharton, Whitney
Kehoe, Patrick
Zissimopoulos, Julie
The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title_full The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title_fullStr The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title_full_unstemmed The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title_short The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity
title_sort association of multiple anti-hypertensive medication classes with alzheimer’s disease incidence across sex, race, and ethnicity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211717/
https://www.ncbi.nlm.nih.gov/pubmed/30383807
http://dx.doi.org/10.1371/journal.pone.0206705
work_keys_str_mv AT bartholddouglas theassociationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT joycegeoffrey theassociationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT whartonwhitney theassociationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT kehoepatrick theassociationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT zissimopoulosjulie theassociationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT bartholddouglas associationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT joycegeoffrey associationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT whartonwhitney associationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT kehoepatrick associationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity
AT zissimopoulosjulie associationofmultipleantihypertensivemedicationclasseswithalzheimersdiseaseincidenceacrosssexraceandethnicity